NVNO

enVVeno Medical Corporation [NVNO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NVNO Stock Summary

Top 10 Correlated ETFs

NVNO

Top 10 Correlated Stocks

NVNO

In the News

NVNO Financial details

Company Rating
-
Market Cap
66.45M
Income
-22.75M
Revenue
824K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-2.27
Forward P/E
-
PEG
2.33
P/S
-
P/B
2.07
P/C
-
P/FCF
-3.45
Quick Ratio
12.65
Current Ratio
12.91
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.95
EPS next Y
-
EPS next Q
-
EPS this Y
-11.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-30.87%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-6.67%
-
-
-
-
SMA20
-
SMA50
-66.67%
SMA100
-75%
Inst Own
-
Inst Trans
-
ROA
-81%
ROE
-72%
ROC
-0.98%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.51-6.97
52W High
-88.58%
52W Low
-65.74%
RSI
29
Rel Volume
1.73
Avg Volume
131.62K
Volume
228.22K
Perf Week
-3.51%
Perf Month
-26.58%
Perf Quarter
-81.02%
Perf Half Y
-75.26%
-
-
-
-
Beta
1.116
-
-
Volatility
0.01%, 0.11%
Prev Close
-4.67%
Price
0.6852
Change
-2.25%

Something similar

Top by Market Cap
EMBASSY.NS
FB2A.DE
CMC.DE
3V64.DE
BRK-B
Top Correlated ETFs
ENFR
USAI
TBT
TTT
TMV
Top Correlated Stocks
REDC.L
MOS
0K3B.L
DOCS
VG
Similar Market Cap
SLBEN.LS
QRT.L
DXO.TO
AMES.DE
PYR

Company Profile

Healthcare Medical - Devices
  • Volume Average 131.62K
  • Market Capitalization 66.45M
  • Employee 31
  • CEO Mr. Robert A. Berman
  • Headquarters Irvine,CA,US
  • IPO Date 2018-05-31
  • Website https://www.envveno.com

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.